Decreasing microbiota-derived uremic toxins to improve CKD outcomes

Area of Science:

• Nephrology
• Microbiology
• Gastroenterology

Background:

• Chronic kidney disease (CKD) is a growing global health concern, projected to be the fifth leading cause of death by 2040.
• Significant knowledge gaps exist regarding CKD pathogenesis and effective therapies.
• The intricate relationship between CKD and the gut microbiome is a critical, yet underexplored, area.

Purpose of the Study:

• To review the complex interactions between the gut microbiome and chronic kidney disease.
• To explore how CKD influences the gut microbiota and vice versa.
• To discuss novel therapeutic strategies emerging from this understanding.

Main Methods:

• Literature review of studies investigating the gut microbiome in CKD.
• Analysis of bidirectional interactions between microbial metabolites and CKD progression.
• Evaluation of current and emerging therapeutic interventions targeting the microbiome.

Main Results:

• Uremic toxins, like urea, alter gut microbiota composition and function.
• Dietary and pharmacological interventions significantly impact the gut microbiome in CKD.
• The gut microbiota produces metabolites that can influence CKD manifestations and uremic toxin levels.

Conclusions:

• The gut microbiome plays a crucial role in CKD pathogenesis and progression.
• Targeting the gut microbiome offers promising avenues for novel CKD therapies.
• Interventions include dietary changes, prebiotics, probiotics, synbiotics, postbiotics, and enhanced toxin clearance.